Hemasphere

Papers
(The TQCC of Hemasphere is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
PB1708: CHARACTERIZATION OF GLOBAL CYTOGENOMICS FEATURES IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA BY OPTICAL GENOME MAPPING107
S233: AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY102
PB2064: THE COMPLETE STUDY: A SINGLE ARM, MULTICENTER OBSERVATIONAL STUDY TO EVALUATE EFFECTIVENESS OF PEGCETACOPLAN UNDER REAL WORLD CONDITIONS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (P76
P401: INNOVATIVE REDUCED-DOSE CHEMOTHERAPY FOLLOWED BY BLINATUMOMAB INDUCTION THERAPY FOR SUCCESSFUL MANAGEMENT OF TREATMENT NAIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ADULTS: A MULTICENTER, REAL-WORLD70
P1672: OCCUPATIONAL INTEGRATION OF ADULTS WITH SEVERE HAEMOPHILIA (INTHEMO): A STUDY BASED ON THE FRANCECOAG REGISTRY65
P480: DNMT AND HDAC INHIBITION INDUCES IMMUNOGENIC NEOANTIGENS FROM HUMAN ENDOGENOUS RETROVIRAL ELEMENT-DERIVED TRANSCRIPTS62
P1586: COMPARISON OF FREQUENCY OF TRANSFUSION RELATED COMPLICATIONS IN THALASSEMIC AND NON-THALASSEMIC PATIENTS RECEIVING NON LEUKODEPLETED RED CELL CONCENTRATE.58
P1571: PREVENTION OF COVID19 IN PATIENTS WITH HEMOBLASTOSIS. OWN CLINICAL EXPERIENCE50
P987: IRAK1 AND JAK2 DUAL INHIBITION WITH PACRITINIB PREVENTS MYELOFIBROSIS-LIKE PHENOTYPE IN AN INFLAMMATION-DRIVEN MURINE MODEL45
P529: THE EFFECT OF AGE AND TREATMENT ON THE PREDICTIVE VALUE OF MEASURABLE RESIDUAL DISEASE: IMPLICATIONS FOR THE CLINICAL MANAGEMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA43
PB2525: A FOUR YEARS’ EXPERIENCE OF UNIVERSAL NEWBORN SCREENING FOR HAEMOGLOBIN DISORDERS IN UDINE, FVG, NORTHERN ITALY43
P1453: ORTHOTOPIC LIVER TRANSPLANT IN SICILIAN HEMOGLOBINOPHATIES PATIENTS39
PB2193: JAK2 V617F MUTATION BURDEN DETECTION AND RELATIONSHIP WITH LABORATORY CHARACTERISTICS IN MYELOPROLIFERATIVE NEOPLASMS38
P404: IMMUNOGLOBULIN GENE REARRANGEMENT IN KOREAN PATIENTS WITH B-LYMPHOBLASTIC LEUKEMIA – AN IMMUNOPHENOTYPE AND REPERTOIRE ANALYSIS38
P1671: CARFILZOMIB-DEXAMETHASONE MAINTENANCE HAMPERS RECOVERY AFTER SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA34
P1093: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ZANUBRUTINIB (ZANU) VERSUS IBRUTINIB (IBRU) IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)34
P702: APPLICATION OF NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) AND CHIMERISM MONITORING IN MYELODYSPLASTIC SYNDROME (MDS) AFTER ALLOGENIC STEM CELL TRANSPLANTATION (ASCT)33
PB2390: STUDY OF GENETIC ALTERATIONS USING A CUSTOM LYMPHOID TARGETED NGS PANEL IN PATIENTS WITH FOLLICULAR LYMPHOMA: A PILOT STUDY33
PB2163: BORTEZOMIB - CYCLOPHOSPHAMIDE – DEXAMETHASONE (VCD) REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) - EXPERIENCE FROM A RESOURCE CONSTRAINT SETTING IN SOUTH INDIA33
PB2203: INCIDENCE AND PREVALENCE OF MYELOFIBROSIS IN GERMANY: A RETROSPECTIVE CLAIMS DATA ANALYSIS32
P1445: THE IMPACT OF ILLNESS PERCEPTION AND STIGMA ON PATIENT-REPORTED OUTCOMES IN SICKLE CELL DISEASE32
P1147: FEASIBILITY AND OUTCOME AFTER DOSE REDUCTION OF IMMUNOCHEMOTHERAPY IN YOUNG ADULTS WITH BURKITT LYMPHOMA AND LEUKEMIA. RESULTS OF THE BURKIMAB14 TRIAL32
PB2381: EFFICACY ANALYSIS OF BRUTON’S TYROSINE KINASE INHIBITOR COMBINED REGIMEN IN THE TREATMENT OF ELDERLY PATIENTS WITH RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA31
P1033: JAKTINIB IN PATIENTS WITH MYELOFIBROSIS WHO WERE REFRACTORY OR RELAPSED TO RUXOLITINIB: A SINGLE-ARM, OPEN-LABEL, MULTICENTER, PHASE 2 STUDY30
B07 HIGH EXPRESSION OF NUCLEAR CEREBLON IS ASSOCIATED WITH LONGER SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMIDS30
S304: WHAT IS A MASSIVE TRANSFUSION? A SCOPING REVIEW TO INFORM AN INTERNATIONAL CONSENSUS DEFINITION29
PB2226: HIGH RISK LANGERHANS CELL HISTIOCYTOSIS (LCH) IN CHILDREN: THE ROLE OF CLADRIBINE SALVAGE IN IMPROVING THE OUTCOME. A SINGLE CENTER EXPERIENCE29
P1683: THE EORTC QLQ-HL27: EORTC PROSPECTIVE INTERNATIONAL VALIDATION OF A DISEASE-SPECIFIC QUESTIONNAIRE FOR ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HODGKIN LYMPHOMA29
PB2083: IN-VITRO EVALUATION OF LENALIDOMIDE ENANTIOMERS AGAINST HUMAN MULTIPLE MYELOMA CELL LINE28
Prediction of the Clinical Course of Immune Thrombocytopenia in Children by Platelet Kinetics28
P899: HOVON 104; LONG TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS28
PB1853: OUTCOMES REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA WITH EXTRAMEDULLARY MANIFESTATIONS AFTER GEMTUZUMAB OZOGAMICIN THERAPY27
PB1815: ADDITIONAL СYTOGENETIC ABNORMALITIES IN ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)27
P780: G-CSF THERAPY IN EUROPEAN PATIENTS WITH SHWACHMAN-DIAMOND SYNDROME26
PB2046: CHANGINGS IN GENETIC DEFINITION AND MANAGEMENT OF ACQUIRED APLASTIC ANEMIA: A SINGLE CENTER EXPERIENCE26
P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA26
P885: SOLITARY PLASMACYTOMA: SINGLE INSTITUTION EXPERIENCE AND SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL OUTCOMES26
P908: IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A25
PB2107: EVOLUTION OF SELECTION CRITERIA FOR PHASE 3 CLINICAL TRIALS IN MULTIPLE MYELOMA.25
P533: A FULLY AUTOMATED SUPERVISED AI-BASED CELL CLASSIFIER TO ACCURATELY FLAG PATHOLOGICAL SIGNATURE CELLS IN 28,285 REAL-WORLD BLOOD SMEARS24
P1681: RACIAL DIFFERENCES IN DETERMINANTS OF TREATMENT DECISION-MAKING AMONG PATIENTS WITH MULTIPLE MYELOMA24
P1298: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC-HSCT IN REFRACTORY/RELAPSED OR PERSISTENT MRD POSITIVITY AML PATIENTS24
PB2449: EFFECT OF MOBILIZATION METHODS ON CD34+ AND TOTAL NUCLEATED CELL COUNT AND THEIR RELATION WITH ENGRAFTMENT IN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION23
P1379: DEVELOPMENT OF A GENE THERAPY CELL DEATH-INDUCING SYSTEM REGULATED BY MICRORNAS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA.23
P1677: DEFINING KEY QUALITY OF LIFE METRICS IN ACUTE MYELOID LEUKAEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME PATIENTS ENROLLED IN LARGE-SCALE UK NCRI AML TRIALS23
PB2421: EPSTEIN-BARR VIRUS-ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE: RESULTS OF A DELPHI STUDY IN SPAIN.23
P1000: JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) INHIBITS T CELL PROLIFERATION VIA THE ECTONUCLEOTIDASE CD39 AND THE PURINERGIC NETWORK23
PB2356: OUTCOMES OF PATIENTS WITH PRIMARY CNS LYMPHOMA (PCNSL) WHO UNDERWENT TREATMENT WITH DEANGELIS, MATRIX, AND PRIMAIN PROTOCOL.: A RETROSPECTIVE SINGLE-CENTER STUDY23
PB1772: HIGH SLIT2 LEVELS ARE ASSOCIATED WITH GMP LIKE AML AND TREATMENT WITH RECOMBINANT SLIT2 INHIBITS LEUKEMOGENESIS22
S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION22
P927: ACTUAL USAGE OF CURRENT SYSTEMIC TREATMENTS AND INFLUENCE OF KEY DRIVERS FOR MULTIPLE MYELOMA IN THE FIRST 2 LINES OF THERAPY. DATA FROM REAL-WORLD STUDY IN EU5 COUNTRIES.22
P687: EARLY RESULTS OF A PHASE II STUDY EVALUATING THE ADDITION OF ASCIMINIB TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA22
P743: CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS21
P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML21
P372: CMV REACTIVATIONS/INFECTIONS IN PH+ ALL PATIENTS TREATED WITH DASATINIB WITH OR WITHOUT BLINATUMOMAB. A RETROSPECTIVE MULTICENTER CAMPUS ALL STUDY21
P706: RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISKMYELODYSPLASTIC SYNDROME (HR-MDS): THE ROLE OF THE ADENOSINEDEAMINASE ACTING ON RNA 1 (ADAR1) ENZYME20
PB2174: DISSECTING THE MECHANISM OF INTERFERON ALFA (IFNΑ) RESPONSE IN MYELOPROLIFERATIVE NEOPLASM AND IDENTIFICATION OF PREDICTORS OF RESPONSE20
S241: ITACONATE INHIBITS TH1 DIFFERENTIATION AND ACUTE GRAFT-VERSUS-HOST DISEASE VIA NRF220
PB2148: IMPACT OF OBESITY IN THE CLINICAL OF MULTIPLE MYELOMA PATIENTS: A REPORT FROM MMRF DATASET20
P1380: THE COMPOSITION OF INFUSED CD19-CAR-T PRODUCT IMPACTS ON EFFICACY20
PB2085: EPIDEMIOLOGICAL DESCRIPTION AND PROGNOSIS FEATURES OF MULTIPLE MYELOMA IN A TUNISIAN HAEMATOLOGY CENTER20
PB2501: INSIGHT-1: A PHASE I FIRST-IN-HUMAN TCR TRIAL OF GENETICALLY MODIFIED T-CELLS TARGETING TDT IN CHILDREN AND ADULTS WITH T- AND B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (TRIAL-IN-PROGRESS)19
P993: INCREASED STAT5B LEVELS IN MYELOPROLIFERATIVE NEOPLASMS LEAD TO ENHANCED MEGAKARYOCYTIC DIFFERENTIATION CORRELATING WITH THROMBOSIS19
P1635: DETERMINATION OF THE EFFECTIVE CONCENTRATION OF TRANEXAMIC ACID NEUTRALIZING IN AN IN VITRO UROKINASE INDUCED HYPERFIBRINOLYTIC MODEL USING A GLOBAL FIBRINOLYTIC CAPACITY ASSAY19
PB2561: DEVELOPMENT OF COLD AGGLUTININ AUTOIMMUNE HEMOLYTIC ANEMIA DURING TREATMENT FOR PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: A CASE REPORT.18
P602: SINGLE-CELL RNA-SEQUENCING ENABLES TRACKING AND CHARACTERIZATION OF RARE CLL CELLS WITH THE POTENTIAL TO CAUSE REFRACTORINESS.18
PB1727: EVALUATION OF POST-TREATMENT SECONDARY CANCERS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH MODIFIED ST. JUDE TOTAL XIII AND TOTAL XV PROTOCOLS.18
PB2672: EXPLORING UNMET NEEDS OF PATIENTS WITH MYELODYSPLASTIC NEOPLASMS AND CAREGIVERS IN A NATIONAL ITALIAN SURVEY18
PB2443: APPLICABILITY OF SHORT TANDEM REPEAT (STR) IN LEUKEMIA PATIENTS RECEIVED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE ERA OF MINIMAL RESIDUAL DISEASE (MRD)18
P050: Reed-Sternberg cells accelerate glycolytic and mitochondrial metabolism of tumor microenvironment cells17
T084: Treatment patterns and outcomes for Hodgkin’s Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s lymphoma Registry17
PB2391: FREQUENCY OF IKZF3 MUTATION IN WALDENSTRÖM’S MACROGLOBULINEMIA17
P011: IPS-7 or IPS-3 to identify very-high risk patients in advanced Classical Hodgkin’s Lymphoma: Which score to choose17
P-073: SICKLE CELL ANEMIA: MAPPING AND MOLECULAR CHARACTERIZATION OF HEMOGLOBIN MUTATIONS AND THEIR CLINICAL CORRELATION IN TRIBAL AND NON-TRIBAL POPULATIONS OF MADHYA PRADESH.17
P500: SUPERIOR OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AMONG PATIENTS ≥ 60 YEARS TREATED WITH CLADRIBINE, LOW DOSE CYTARABINE PLUS VENETOCLAX FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA16
P-070: PLANNING IMPLEMENATION OF PEDIATRIC-TO-ADULT CARE TRANSITION IN SICKLE CELL DISEASE IN BRAZIL16
5613274 “A PICTURE IS OFTEN WORTH MORE THAN MANY WORDS: STREET ART AS EMPOWERMENT FOR SICKLE CELL DISEASE PATIENTS” JACKELINE ELIZABETH MARAN1, MARINA PERDIBON1, ILARIA BAIDO1, MICHEL NKONGNE GYSLENE216
P-040: RED BLOOD CELLS ADHESION AND OCCLUSION INDEX IN A PATIENT WITH SICKLE CELL DISEASE PRIOR AND POST HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)16
P1281: REFRACTORY PATIENTS WITH FAVORABLE/INTERMEDIATE-RISK AML BENEFIT FROM AZACYTIDINE MAINTENANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION16
P489: PROGNOSTIC IMPACT OF “MULTI-HIT” VERSUS “SINGLE-HIT” TP53 MUTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS FROM THE CONSORTIUM ON MYELOID MALIGNANCIES AND NEOPLASTIC DISEASES (COMMAND)16
5559749 A MULTICENTER, RETROSPECTIVE STUDY ON REAL-WORLD EXPERIENCE OF PATIENTS WITH SICKLE CELL DISEASE TREATED WITH VOXELOTOR16
5612571 EARLIER PRENATAL DIAGNOSIS OF HEMOGLOBINOPATHIES BY CELOCENTESIS16
P1489: HIGH DOSE IRON IMPAIRS MALIGNANT B-CELL VIABILITY AND IMPROVES IMMUNE ANTITUMOR FUNCTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA16
P-016: DEVELOPMENT OF A CLINICAL SEVERITY SCORING SYSTEM FOR INDIAN SICKLE CELL ANAEMIA PATIENTS16
P1241: A NOVEL CEREBLON-BINDING MOLECULAR GLUE, SP-3164, SHOWS PRECLINICAL ACTIVITY IN NON-HODGKIN LYMPHOMAS16
Issue Information15
P1463: HEALTHCARE RESOURCE USE, ECONOMIC BURDEN AND IN-PATIENT MORTALITY IN PATIENTS WITH ALPHA- AND BETA-THALASSEMIA COMPARED TO MATCHED CONTROLS IN THE REAL-WORLD SETTING15
P1584: PREVELANCE OF ABO DISCPRENACIES AND ITS CLASSIFACTION IN BLOOD DONORS AT REGIONAL BLOOD CENTRE, KARACHI.15
P772: LONG-TERM RAVULIZUMAB TREATMENT IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PNH PROVIDES DURABLE CONTROL OF INTRAVASCULAR HEMOLYSIS WITH LOW INCIDENCE OF MAJOR ADVERSE VASCULAR EVENTS AND 15
Efficacy of anti‐PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA15
S182: ORAL IPTACOPAN MONOTHERAPY INCREASES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE VIA CONTROL OF INTRA- AND EXTRAVASCULAR HEMOLYSIS IN ANTI-C5-TREATED PNH PATIENTS WITH AN15
P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS15
When to stop: Transfusions, difficult conversations and creativity15
PB2267: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-1)15
P363: A PHASE II STUDY OF FLUMATINIB WITH CHEMOTHERAPY FOR NEWLY DIAGNOSED PH/BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN ADULTS: UPDATED RESULTS FROM RJ-ALL2020.2A TRIAL15
P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL15
Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study14
Lower efficacy of transfusion of red blood cells from donors with sickle cell trait14
Why Do We Diagnose Monoclonal B-cell Lymphocytosis? Five Questions14
P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS14
P1044: REDUCTION IN RED BLOOD CELL TRANSFUSION BURDEN: A NOVEL LONGITUDINAL TIME-DEPENDENT ANALYSIS IN PATIENTS WITH TRANSFUSION-DEPENDENT MYELOFIBROSIS TREATED WITH MOMELOTINIB14
Biomarker‐adapted treatment in high‐risk large B‐cell lymphoma14
Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry14
AP-1 Transcription Factor Complex Members FOSB and FOS are Linked With CNS Infiltration and Inferior Prognosis in Childhood T-ALL14
P1262: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH FLT3–INTERNAL TANDEM DUPLICATION MUTATION14
Issue Information13
P1223: IMAGING MASS CYTOMETRY REVEALS A HIGHLY HETEROGENOUS CELL MAKEUP AND SPATIAL CONTEXT OF THE FOLLICULAR LYMPHOMA TUMOR MICROENVIRONMENT13
Antibiotic‐associated neutropenia is marked by the depletion of intestinal Lachnospiraceae and associated metabolites in pediatric patients13
S224: HIGH COMPLETE RESPONSE RATE WITH TNB-486, A NOVEL CD19XCD3 T-CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY13
P880: EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A SUBGROUP ANALYSIS FROM MAGNETISMM-313
Varnimcabtagene autoleucel (ARI‐0001) in relapsed or refractory mantle cell lymphoma13
PB2350: HEMATOLOGIC MALIGNANCIES AND AUTO-IMMUNITY: A CASE SERIES OF 21 PATIENTS13
Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)‐MCL0208 clinical trial13
PB1784: CLADRIBINE SYNERGIZES THE EFFECT OF VENETOCLAX ON CELL PROLIFERATION ARREST AND APOPTOSIS BY TARGETING DNA-PKCS/C-MYC SIGNALING IN ACUTE MYELOID LEUKEMIA13
12
P479: TREATMENT IS SHAPING CLONAL EVOLUTION AND RESISTANCE PATTERNS IN MURINE KMT2A-REARRANGED LEUKEMIA WITH SUBCLONAL FLT3N676K12
First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial12
Strengthening awareness and response to HTLV‐1 infection in Africa: A neglected threat to blood safety and public health12
Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia12
S180: RESULTS OF A PHASE 3 TRIAL OF AN ORAL CXCR4 ANTAGONIST, MAVORIXAFOR, FOR TREATMENT OF PATIENTS WITH WHIM SYNDROME12
Real‐world, multi‐omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS)12
Temporal Trends in the Incidence of Hemophagocytic Lymphohistiocytosis: A Nationwide Cohort Study From England 2003–201812
Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma12
EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation12
Annual Sickle Cell & Thalassaemia Conference (ASCAT) ‐ October 202312
IDALLO study: A retrospective multicenter study of the SFGM‐TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1‐mutated AML after allogeneic hematopoietic cell transplantation12
Bone marrow niches for hematopoietic stem cells12
P409: BCL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA12
PB2370: EXTRANODAL NATURAL KILLER (NK)/T-CELL LYMPHOMA, NASAL-TYPE: ABOUT 11 CASES11
PB1909: LOW-BURDEN TP53 MUTATIONS REPRESENT FREQUENT GENETIC EVENTS IN CLL WITH AN INCREASED RISK FOR TREATMENT INITIATION11
P1438: L-GLUTAMINE: A NOVEL AND EFFECTIVE THERAPEUTIC TOOL FOR VOC REDUCTION IN SCD11
PB2061: A NEW DIAGNOSTIC TOOL BASED ON MOLECULAR APPROACHES APPLICABLE TO ROUTINE CLINICAL USE FOR FANCONI ANEMIA PATIENTS ORIGINATING FROM NORTH AFRICA11
P685: LATE PHASE BCR-ABL DECLINE PREDICTS THE DURATION OF TKI (IMATINIB) FOR SUCCESSFUL TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA.11
P1105: NEUROLOGIC INVOLVEMENT IN ADULTS WITH ROSAI-DORFMAN DISEASE: CLINICAL PRESENTATION AND OUTCOMES11
PB2543: CIRCULATING MICROVESICLES AS POTENTIAL CELLULAR BIOMARKERS FOR THROMBOTIC RISKS IN BETA THALASSEMIA11
P614: NOVEL SPLICE-SITE MUTATION IN PLCG2 ASSOCIATED WITH RESISTANCE TO BTK INHIBITORS11
PB2619: THE IMPACT OF ITP-DIRECTED TREATMENT ON FATIGUE AMONG CHILDREN AND ADOLESCENTS WITH CHRONIC ITP: DATA FROM THE ITP NATURAL HISTORY STUDY REGISTRY11
P1527: ASSESSMENT OF RISK FACTORS AND ANTIMICROBIAL THERAPY FOR CARBAPENEM-RESISTANT PSEUDOMONAS AERUGINOSA BLOODSTREAM INFECTIONS IN HEMATOLOGICAL PATIENTS11
P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSI11
PB2149: MINIMAL RESIDUAL DISEASE (MRD) DETECTION TRENDING AS A PRIMARY ENDPOINT IN CERBA RESEARCH MULTIPLE MYELOMA (MM) TRIALS11
PB1808: EPIGENETIC INHIBITOR SCREEN TO IDENTIFY THERAPEUTIC CANDIDATES FOR MNX1-OVEREXPRESSING AML11
P1630: A 2022 CROSS-NATIONAL SURVEY OF PEOPLE LIVING WITH HAEMOPHILIA DURING THE COVID-19 PANDEMIC: VIEWS ON VACCINATION- AND INFECTION-RELATED RISKS11
P986: COMBINATION JAK1/2 AND CDK8/19 INHIBITION DEMONSTRATES ENHANCED EFFICACY IN MYELOPROLIFERATIVE NEOPLASMS11
P337: IKZF1 DELETIONS IN B-ALL: FROM ITS GENETIC BASIS TO DIAGNOSTIC ENHANCEMENT11
PB2143: PROGNOSTIC SIGNIFICANCE AND CLINICAL APPLICABILITY OF THE COMORBIDITY INDICES IN PATIENTS WITH MULTIPLE MYELOMA: IMWG AND SARC-F SCORE10
P1526: THE RISK OF DEVELOPING PNEUMOCYSTIS JIROVECII PNEUMONIA PERSISTS EVEN AFTER COMPLETION OF IMMUNOSUPPRESSANTS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS10
P939: THE RELATIONSHIP OF BONE MARROW FIBROSIS WITH EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA10
PB2245: POLYCYTHEMIA VERA (PV) AND SECONDARY POLYCYTHEMIA (SP): ARE METABOLIC DIFFERENCES JUST THEORIES?10
P49 A REAL-WORLD RETROSPECTIVE-PROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF COMBINED IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE NORTHERN ITALY EXPERIENCE10
PB1747: OUTCOME OF CHILDHOOD ALLTREATED WITH ALL BFM IC 2009 PROTOCOL10
P1110: REAL-WORLD TREATMENT PATTERNS OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) IN COMMUNITY ONCOLOGY PRACTICES IN THE UNITED STATES (US)10
PB1744: THE RATIO OF ABSOLUTE LYMPHOCYTE COUNT AT INTERIM OF THERAPY TO ABSOLUTE LYMPHOCYTE COUNT AT DIAGNOSIS PREDICTS SURVIVAL IN ACUTE LYMPHOBLASTIC LEUKEMIA10
P970: A REAL-WORLD RETROSPECTIVE-PROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF COMBINED IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE NORTHERN ITALY EXPERIENCE10
P1507: A PREDICTIVE MODEL OF HERPES ZOSTER AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: VZV REACTIVATION AFTER ANTIVIRAL PROPHYLAXIS DISCONTINUATION10
P-014: USE OF OXYGEN GRADIENT EKTACYTOMETRY TO MEASURE EFFICACY IN CELL-BASED THERAPIES10
P-068: SOCIO-ECONOMIC ASPECTS OF SICKLE CELL DISEASE CASES IN ODISHA, INDIA10
P876: ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND DARATUMUMAB OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA—FINAL EFFICACY AND SAFETY RESULTS10
PI-04: OXYGEN GRADIENT EKTACYTOMETRY-DERIVED BIOMARKERS ARE ASSOCIATED WITH THE OCCURRENCE OF ACUTE COMPLICATIONS IN SICKLE CELL DISEASE10
PB2433: APPLICATION GENE VARIATION DETECTION BEFORE AND AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION TO PREDICT THE RELAPSE OF PATIENTS AFTER TRANSPLANTATION: RETROSPECTIVE DATA FROM A SINGLE CENTER 10
P1655: DEEP VENOUS THROMBOSIS IN PATIENT WITH ATRESIA OF INFERIOR VENA CAVA AND RIGHT KIDNEY HYPOPLASIA (KILT SYNDROME): CASE REPORT AND SYSTEMATIC REVIEW OF THE LITERATURE10
P1503: ETIOPATHOGENESIS OF CANCER-RELATED ANEMIA AMONG CHILDREN AND ADOLESCENTS WITH MALIGNANT SOLID TUMORS10
PB1740: THE COMBINATION OF PONATINIB PLUS CHEMOTHERAPY UPFRONT ACHIEVES DURABLE COMPLETE MOLECULAR REMISSIONS IN ADULTS PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMI10
P047: Predictive role of the Hodgkin lymphoma-associated cytokines: a prospective study of the Czech Hodgkin Study Group10
PB2154: THE IMPACT OF DISEASE SEVERITY ON THE CLINICAL AND ECONOMIC BURDEN OF AL AMYLOIDOSIS10
P1290: UPFRONT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CAN PROVIDE SURVIVAL BENEFIT VERSUS HYPOMETHYLATING AGENT IN MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS I (MDS-IBI)10
PB1766: IN VITRO ACQUIRED RESISTANCE TO THE ORAL MYELOID KINASE INHIBITOR TUSPETINIB CREATES SYNTHETIC LETHAL VULNERABILITY TO VENETOCLAX10
P534: FIRST-IN-HUMAN TRIAL OF TOCILIZUMAB IN COMBINATION WITH A STANDARD INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS: THE PHASE 1 TOCILAM STUDY.9
P1091: CLINICAL IMPLICATIONS OF T CELL SUBSET COMPOSITION DURING MAINTENANCE THERAPY AFTER FIRST-LINE IMMUNOCHEMOTHERAPY CONTAINING BENDAMUSTINE IN PATIENTS WITH FOLLICULAR LYMPHOMA9
P1346: THE IMPACT OF CYTOTOXIC THERAPY ON THE RISK OF PROGRESSION AND DEATH IN PATIENTS WITH CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE.9
5613511 URINARY KIDNEY INJURY MOLECULE 1 AND URINARY MONOCYTE CHEMOTACTIC PROTEIN 1 AS NOVEL BIOMARKERS FOR EARLY DIAGNOSIS OF SICKLE CELL RENAL DYSFUNCTION9
PB2522: LIPID PROFILE AND CARDIAC FUNCTIONS IN EGYPTIAN SICKLE CELL DISEASE PATIENTS: A SINGLE CENTER STUDY9
PB2176: MRNA OF MPL AND JAK2 GENES IN PLATELETS IS ASSOCIATED WITH THEIR ASPIRIN RESISTANCE IN MPN PATIENTS9
P1674: PAP SCORE (PALLIATIVE PROGNOSTIC SCORE) ESTIMATES SHORT-TERM SURVIVAL IN A COHORT OF HEMATOLOGICAL PATIENTS9
P1325: EFFICACY AND SAFETY OF HEROMBOPAG FOR THE TREATMENT OF SECONDARY FAILURE OF PLATELET RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION9
P1660: THROMBOSIS RISK IN PATIENTS WITH ACUTE LEUKEMIA (AL)9
P894: INFECTION RISK BEFORE DIAGNOSIS OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: RESULTS FROM THE SCREENED POPULATION-BASED ISTOPMM STUDY9
P1156: IN THE ABSENCE OF SYMPTOMS OR CEREBROSPINAL FLUID INVOLVEMENT, MRI STAGING OF THE CENTRAL NERVOUS SYSTEM (CNS) IN PATIENTS WITH SYSTEMIC DIFFUSE LARGE B-CELL LYMPHOMA RARELY DETECTS DISEASE9
PB2682: ANTI-NEOPLASTIC TREATMENT, BASED ON PRO DATA REPORTED THROUGH A MHEALTH APP SOLUTION IN MULTIPLE MYELOMA PATIENTS9
P036: Detection of recurrent somatic variants in cell-free DNA as a tool for disease monitoring in Hodgkin lymphoma9
PB2180: TREATMENT CHALLENGES OF COEXISTING MYELOID AND LYMPHOID NEOPLASM- A CASE REPORT9
P033: Clinical significance of the severity of THRLBCL-like areas in nodular lymphocyte predominant Hodgkin lymphoma9
P511: INTEGRATION OF TRANSCRIPTOMIC FEATURES IMPROVES PROGNOSIS PREDICTION OF PEDIATRIC ACUTE MYELOID LEUKEMIA WITH KMT2A REARRANGEMENTS9
S141: INHIBITION OF MYC TRANSLATION THROUGH TARGETING OF THE NEWLY IDENTIFIED PHB-EIF4F COMPLEX AS THERAPEUTIC STRATEGY INCHRONIC LYMPHOCYTIC LEUKEMIA (CLL)9
P1370: A NOVEL GENE THERAPY VECTOR FOR BETA-HEMOGLOBINOPATHIES WITH A SELECTIVE EXPANSION CASSETTE9
P592: SINGLE-CELL RNA SEQUENCING REVEALS THE SPATIAL HETEROGENEITY OF EXHAUSTED T CELLS IN BTKI-RESISTANT RICHTER TRANSFORMATION PATIENTS9
5613327 KNOCK-DOWN OF AUTOPHAGY-RELATED GENE 5 (ATG5) EXPRESSION IN THALASSEMIC CD34+ CELLS LEADS TO AMELIORATION OF ERYTHROPOIESIS9
PB2601: BLOOD POLLUTION IN THE AGE OF NANO9
T066: Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study9
PB2408: PREVALENCE OF METABOLIC SYNDROME IN LONG TERM HEMATOPOIETIC STEM CELL TRANSPLANTATION SURVIVORS: COMPARISON WITH A MATCHED REFERENCE COHORT.9
P1667: ATTRIBUTES OF RANDOMIZED CONTROLLED TRIALS AND THEIR ASSOCIATIONS WITH FUNDING SOURCE IN VENOUS THROMBOEMBOLISM PROPHYLAXIS FOR PATIENTS WITH CANCER: A BIBLIOGRAPHICAL ANALYSIS9
S104: DIFFERENTIAL TARGET PROFILES AND EFFICACY OF ADCLEC.SYN1 AND CD33-CARS IN HUMANIZED AML MODELS8
PB1932: RETROSPECTIVE STUDY OF BURDEN OF INFECTION IN PATIENTS WITH AND WITHOUT SECONDARY IMMUNODEFICIENCY DISEASE FOLLOWING DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKAEMIA8
P089: Pembrolizumab in Pediatric and Young Adults Patients With Newly Diagnosed Classical Hodgkin Lymphoma and Slow Early Responders to Frontline Chemotherapy: The Phase 2 KEYNOTE-667 Study8
P1471: SUSTAINED EFFICACY OF SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, IN PATIENTS WITH COLD AGGLUTININ DISEASE: RESULTS FROM PART B OF THE PHASE 3 CADENZA STUDY8
Issue Information8
Delving deeper into the pathogenesis and genomics of posttransplant diffuse large B‐cell lymphoma8
An integrated classification of tumor suppressor IKZF1 inactivation and oncogenic activation in Philadelphia chromosome‐like acute lymphoblastic leukemia8
Efficacy and safety of steroid‐sparing strategy in the treatment of AIHA associated with KSHV/HHV‐8 positive multicentric Castleman disease8
P-035: RED BLOOD CELL ALLOIMMUNIZATION IN SICKLE CELL DISEASE PATIENTS IN THE DEMOCRATIC REPUBLIC OF THE CONGO8
P1517: HUMORAL AND CELLULAR IMMUNE RESPONSES TO SARS-COV-2 NATURAL INFECTION OR VACCINATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A STUDY BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CL8
P-032: INTEGRATIVE DIAGNOSIS OF SICKLE CELL DISEASE PATIENTS FOR PERSONALIZED MEDICINE8
S143: NATURAL CLONAL EVOLUTION OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH BIMODAL CD49D EXPRESSION REVEALS CD49D PLASTICITY8
P787: ALTERNATIVE PATHWAY MASP-3 INHIBITOR OMS906: RESULTS FROM A FIRST-IN-MAN PHASE 1 STUDY IN HEALTHY SUBJECTS AND STUDY DESIGN OF TWO ONGOING CLINICAL TRIALS IN PATIENTS WITH PNH8
PRC2‐mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and monosomy 78
Implementation science in hemato‐oncology molecular diagnostics in France via the Groupe des Biologistes Moléculaire des Hémopathies Malignes (GBMHM)8
Biological and clinical characteristics of ETV6 :: RUNX1 ‐like ALL8
Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival8
Correction Notice – Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study8
PB2026: ROLE OF MOLECULAR PROFILING IN MYELODYSPLASTIC SYNDROME IN REAL-WORLD - A NEW APPROACH IN MYELODYSPLASTIC SYNDROME’S RISK STRATIFICATION?8
P379: PONATINIB AND BLINATUMOMAB IN RELAPSED/REFRACTORY PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR CHRONIC MYELOID LEUKEMIA IN LYMPHOID BLAST PHASE: SUBGROUP ANALYSIS FROM A PHASE II TRIAL8
P1270: MYELOABLATIVE FRACTIONATED BUSULFAN-BASED CONDITIONING REGIMEN IN PATIENTS WITH AML AND MDS: RESULTS OF A RANDOMIZED CLINICAL TRIAL COMPARING 2 FRACTIONATION SCHEDULES8
PB1918: HIGH BAX/BCL-2 RATIO IS ASSOCIATED WITH GOOD PROGNOSIS AND BETTER SURVIVAL IN PATIENTS WITH B CELL CHRONIC LYMPHOCYTIC LEUKEMIA8
T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Gro8
P629: THE CLL TREATMENT INFECTION MODEL – CLINICAL PROSPECTIVE VALIDATION AS PART OF THE PREVENT-ACALL TRIAL8
7
PB2002: ASSOCIATION OF GENE MUTATIONS AND CLINICAL MANIFESTATIONS AND PROGNOSIS IN THE CLINICAL COHORT WITH 218 MDS PATIENTS7
Impact of Mutational Status and Prognostic Factors on Survival in Chronic Myelomonocytic Leukemia With Systemic Inflammation and Autoimmune Disorders7
P1565: INCIDENCE OF PNEUMOCYSTIS JIROVECII PNEUMONIA IN PATIENTS WITH B-LINEAGE LYMPHOMA RECEIVING CHEMOTHERAPY CONTAINING RITUXIMAB7
PB2346: ZUMA-24: A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA GIVEN WITH CORTICOSTEROIDS IN THE OUTPATIENT SETTING7
A single JAK2 ‐V617F hematopoietic stem cell can initiate myeloproliferative neoplasm when transplanted into non‐conditioned recipient mice7
PB1964: COMPARISON OF CLINICO-HEMATOLOGICAL PARAMETERS AND MOLECULAR AND CYTOGENETIC RESPONSE OF TWO BCR-ABL FUSION TRANSCRIPTS IN CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB7
PB2671: AN INVESTIGATION INTO THE PREFERENCES OF PATIENTS REGARDING THE USE OF TELEMEDICINE STEMMING FROM THE COVID-19 PANDEMIC.7
P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY7
PB2371: MCP-1-CCR2-M2 MACROPHAGES AXIS CONTRIBUTES TO DIFFUSE LARGE B-CELL LYMPHOMA PROGRESSION AND INHIBITS ANTITUMOR IMMUNE RESPONSE7
PB1820: THE EFFECT OF CONVENTIONAL CHEMOTHERAPY AFTER EXITING QUIESCENT STATE IN ACUTE MYELOID LEUKAEMIA7
P1518: INFECTIONS FOLLOWING BISPECIFIC ANTIBODIES IN MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS7
Eltrombopag Preserves the Clonogenic Potential of Hematopoietic Stem Cells During Treatment With Antithymocyte Globulin in Patients With Aplastic Anemia7
P-083: IMPACT OF ALPHA THALASSEMIA COEXISTENCE ON TRANSFUSION NEED AMONG PATIENTS WITH SICKLE CELL DISEASE7
7
P1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS7
S151: COMBINATION OF LARGE SPLEEN AND LOW IN VIVO KINASE INHIBITION IS AN EARLY PREDICTOR OF INFERIOR MOLECULAR RESPONSE AND POOR OUTCOMES IN CHRONIC MYELOID LEUKAEMIA7
Context-dependent T-cell Receptor Gene Repertoire Profiles in Proliferations of T Large Granular Lymphocytes7
Targeting the Second Transferrin Receptor as Emerging Therapeutic Option for β-Thalassemia Major7
S169: MODULATION OF THE IMMUNE LANDSCAPE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES WITH IMETELSTAT-INDUCED TRANSFUSION INDEPENDENCY7
P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment7
P-071: HEMATOLOGICAL PROFILE AND ITS INTERRELATIONSHIPS WITH HEMOGLOBIN SUBTYPES IN SICKLE CELL DISEASE PATIENTS OF CHHATTISGARH7
PB2594: BACTEREMIA AND FEBRILE NEUTROPENIA IN PATIENTS TREATED FOR ACUTE LEUKEMIA7
Luspatercept versus mitapivat for non‐transfusion‐dependent β‐thalassemia: Dare to compare?7
S142: FOXO1-RICTOR AXIS INDUCES ADAPTIVE INCREASE IN AKT ACTIVITY DURING BCR INHIBITOR THERAPY IN CLL: IMPLICATIONS FOR COMBINATION THERAPY7
Plenary Abstracts Session & Oral Presentations7
P354: MULTI-INSTITUTIONAL STUDY EVALUATING THE IMPACT ON SURVIVAL OF NEWER TREATMENT COMBINATIONS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKE7
Cellular therapies for sickle cell disease: Should we be calling them a cure?7
Biomolecular Condensates in Myeloid Leukemia: What Do They Tell Us?7
Should flow cytometry be required for CMML diagnosis? Position of the ELN iMDS Flow Working Group7
PB2070: IMMUNE RESPONSES AFTER SARS-COV-2 MRNA-VACCINATION AND INFECTION AT SINGLE CELL RESOLUTION IN PATIENTS WITH MULTIPLE MYELOMA7
P751: UNRAVELING THE DIFFERENT PATHOMECHANISMS OF CONGENITAL AND CYCLIC NEUTROPENIAS: CYCLIC EXPRESSION OF HEMATOPOIETIC STEM-CELL-SPECIFIC TRANSCRIPTION FACTORS IN CYCLIC NEUTROPENIA7
P556: A NEW MULTIPLEX PCR TOOL ENABLES TIMELY IDENTIFICATION OF ACTIONABLE TARGETS FOR MOLECULAR-GUIDED THERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA7
P513: MOLECULAR PATTERN BY AGE AND OVERALL SURVIVAL IN ACUTE MYELOID LEUKEMIA: A POPULATION-BASED STUDY FROM THE SWEDISH AML REGISTRY.7
PB1702: ACTIVINA MODULATES THE MICRORNA CARGO OF EXTRACELLULAR VESICLES RELEASED BY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL) CELLS7
PB2363: R-MPV FOLLOWED BY CONSOLIDATION REDUCED-DOSE WHOLE-BRAIN RADIOTHERAPY AND CYTARABINE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA: REAL WORLD DATA7
0.066264152526855